

STANDING ORDERS FOR Administering Pneumococcal Vaccines (PCV13 and PPSV23) to Adults

Purpose

To reduce morbidity and mortality from pneumococcal disease by vaccinating all adults who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

Policy

Where allowed by state law, standing orders enable eligible nurses and other health care professionals (e.g., pharmacists) to assess the need for vaccination and to vaccinate adults who meet any of the criteria below.

Procedure

1 Assess Adults for Need of Vaccination against *Streptococcus pneumoniae* (pneumococcus) infection according to the following criteria:

Routine pneumococcal vaccination

Assess adults age 65 years or older for need of pneumococcal vaccination. Pneumococcal conjugate vaccine (PCV13) should be administered routinely to all previously unvaccinated adults age 65 years and older. Pneumococcal polysaccharide vaccine (PPSV23) is recommended for all adults ages 65 years or older. For complete details, see section 5 (page 2).

Risk-based pneumococcal vaccination

Age 19 through 64 years with an underlying medical condition or other risk factor as described in the following table:

| CATEGORY OF UNDERLYING MEDICAL CONDITION OR OTHER RISK FACTOR | RECOMMENDED VACCINES ARE MARKED "X" BELOW | | |
|---|---|--------|-----------------|
| | PCV13 | PPSV23 | PPSV23 booster* |
| Chronic heart disease, ¹ chronic lung disease ² | | x | |
| Diabetes mellitus | | x | |
| Chronic liver disease, cirrhosis | | x | |
| Cigarette smoking | | x | |
| Alcoholism | | x | |
| Cochlear implant, cerebrospinal fluid leak | x | x | |
| Sickle cell disease, other hemoglobinopathy | x | x | x |
| Congenital or acquired asplenia | x | x | x |
| Congenital or acquired immunodeficiency, ³ HIV | x | x | x |
| Chronic renal failure, nephrotic syndrome | x | x | x |
| Leukemia, lymphoma | x | x | x |
| Generalized malignancy, Hodgkin disease | x | x | x |
| Iatrogenic immunosuppression ⁴ | x | x | x |
| Solid organ transplant, multiple myeloma | x | x | x |

* a second dose 5 years after the first dose of PPSV23

1 Excluding hypertension
 2 Including asthma

3 Including B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease)

4 Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy

CONTINUED ON THE NEXT PAGE ►

2 Screen for Contraindications and Precautions

Contraindications

Do not give pneumococcal vaccine (PCV13 or PPSV23) to a person who has experienced a serious systemic or anaphylactic reaction to a prior dose of the vaccine or to any of its components. For a list of vaccine components, refer to the manufacturer’s package insert (www.immunize.org/packageinserts) or go to www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf.

Precautions

Moderate or severe acute illness with or without fever

3 Provide Vaccine Information Statements

Provide all patients with a copy of the most current federal Vaccine Information Statement (VIS). Provide non-English speaking patients with a copy of the VIS in their native language, if one is available and desired; these can be found at www.immunize.org/vis. (For information about how to document that the VIS was given, see section 6 titled “Document Vaccination.”)

4 Prepare to Administer Vaccine

PCV13 must be given intramuscularly (IM). PPSV23 may be administered either IM or subcutaneously (Subcut). **For vaccine that is to be administered IM**, choose the needle gauge, needle length, and injection site according to the following chart:

| GENDER AND WEIGHT OF PATIENT | NEEDLE GAUGE | NEEDLE LENGTH | INJECTION SITE |
|----------------------------------|--------------|---------------|-----------------------|
| Female or male less than 130 lbs | 22–25 | 5/8"*-1" | Deltoid muscle of arm |
| Female or male 130–152 lbs | 22–25 | 1" | Deltoid muscle of arm |
| Female 153–200 lbs | 22–25 | 1–1½" | Deltoid muscle of arm |
| Male 153–260 lbs | 22–25 | 1–1½" | Deltoid muscle of arm |
| Female 200+ lbs | 22–25 | 1½" | Deltoid muscle of arm |
| Male 260+ lbs | 22–25 | 1½" | Deltoid muscle of arm |

* A 5/8" needle may be used in patients weighing less than 130 lbs (<60 kg) for IM injection in the deltoid muscle only if the skin is stretched tight, the subcutaneous tissue is not bunched, and the injection is made at a 90° angle to the skin.

If you prefer Subcut injection of PPSV23, choose a 23–25 gauge, 5/8" needle for injection into the posterolateral fat of the upper arm.

5 Administer PCV13 or PPSV23, 0.5 mL, according to the following dosing information and schedule:

- PCV13 must be administered by the IM route.
- PPSV23 may be administered either IM or Subcut.

Routine vaccination for all adults ages 65 years and older

| AGE OF PATIENT | VACCINE INDICATED (SEE TABLE ON PAGE 1) | HISTORY OF PRIOR VACCINATION | SCHEDULE FOR ADMINISTRATION OF PCV13 AND PPSV23 |
|-----------------|---|---|---|
| 65 yrs or older | PPSV23 and 1-time dose of PCV13 | None or unknown | Administer PCV13 followed in 1 year* by PPSV23. |
| | | PCV13; PPSV23 when younger than age 65 yrs | Administer another PPSV23 at least 5 years after previous dose of PPSV23 and at least 1 year* after dose of PCV13. |
| | | PPSV23 when younger than age 65 years; 0 or unknown PCV13 | Administer PCV13 at least 1 year* after previous PPSV23. Administer another PPSV23 at least 5 years* after previous dose of PPSV23. |
| | | PCV13 and PPSV23 when younger than age 65 yrs | Administer another PPSV23 at least 5 years after previous dose of PPSV23 and at least 1 year* after previous dose of PCV13. |

* For adults age 65 years and older with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants, the interval between PCV13 and PPSV23 should be shortened to 8 weeks.

CONTINUED ON THE NEXT PAGE ►

Risk-based vaccination for adults ages 19–64 years

| AGE OF PATIENT | VACCINE INDICATED (SEE TABLE ON PAGE 1) | HISTORY OF PRIOR VACCINATION | SCHEDULE FOR ADMINISTRATION OF PCV13 AND PPSV23 |
|----------------|---|-----------------------------------|---|
| 19–64 years | <i>For medical conditions in which only PPSV23 is indicated</i> | | |
| | 1 dose PPSV23 | None or unknown | Administer PPSV23. |
| | <i>For medical conditions in which both PCV13 and PPSV23 (1 or 2 doses) are recommended</i> | | |
| | 1 dose PCV13 and 1 dose PPSV23 | None or unknown | Administer PCV13 followed in 8 weeks by PPSV23. |
| | | 1 dose PCV13; 0 or unknown PPSV23 | Administer PPSV23 at least 8 weeks after PCV13. |
| | | 1 dose PPSV23; 0 or unknown PCV13 | Administer PCV13 at least 1 year after PPSV23. |
| | 1 dose PCV13 and 2 doses PPSV23 | None or unknown | Administer PCV13 followed in 8 weeks by PPSV23 #1. Administer PPSV23 #2 at least 5 years after PPSV23 #1. |
| | | 1 dose PPSV23; 0 or unknown PCV13 | Administer PCV13 at least 8 weeks after PPSV23 #1. Administer PPSV23 #2 at least 5 years after PPSV23 #1. |
| | | 1 dose PCV13; 0 or unknown PPSV23 | Administer PPSV23 #1 at least 8 weeks after PCV13. Administer PPSV23 #2 at least 5 years after PPSV23 #1. |
| | | 1 dose PCV13; 1 dose PPSV23 | Administer PPSV23 #2 at least 5 years after PPSV23 #1 and at least 8 weeks after PCV13. |

6 Document Vaccination

Document each patient’s vaccine administration information and follow up in the following places:

Medical record: Document the date the vaccine was administered, the manufacturer and lot number, the vaccination site and route, and the name and title of the person administering the vaccine. You must also document, in the patient’s medical record or office log, the publication date of the VIS and the date it was given to the patient. If vaccine was not administered, record the reason(s) for non-receipt of the vaccine (e.g., medical contraindication, patient refusal).

Personal immunization record card: Record the date of vaccination and the name/location of the administering clinic.

Immunization Information System (IIS) or “registry”: Report the vaccination to the appropriate state/local IIS, if available.

7 Be Prepared to Manage Medical Emergencies

Be prepared for management of a medical emergency related to the administration of vaccine by having a written emergency medical protocol available, as well as equipment and medications. For IAC’s “Medical Management of Vaccine Reactions in Adults,” go to www.immunize.org/catg.d/p3082.pdf. To prevent syncope, vaccinate patients while they are seated or lying down and consider observing them for 15 minutes after receipt of the vaccine.

8 Report All Adverse Events to VAERS

Report all adverse events following the administration of pneumococcal vaccine to the federal Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov. Forms are available on the website or by calling (800) 822-7967.

Standing Orders Authorization

| |
|---|
| <p>This policy and procedure shall remain in effect for all patients of the _____ <small style="margin-left: 400px;">NAME OF PRACTICE OR CLINIC</small></p> <p>until rescinded or until _____ . <small style="margin-left: 100px;">DATE</small></p> <p>Medical Director’s signature _____ Signature date _____ Effective date _____</p> |
|---|